Iambic Therapeutics

Iambic Therapeutics is a clinical-stage life-sciences and technology company developing novel medicines using its AI-driven discovery and development platform. Founded in 2019 and headquartered in San Diego, California, Iambic combines physics-based AI algorithms with high-throughput experimentation to tackle the most challenging design problems in drug discovery. The company's platform converts new molecular designs to new biological insights each week, enabling it to identify first-in-class and best-in-class drug candidates years faster than industry norms. Iambic's pipeline includes HER2 and CDK2/4 programs in oncology, with its lead HER2 program in Phase 1 clinical studies.